Autorizzazione allo studio clinico sperimentale, farmacologico, profit, denominato: “A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension)” - Codice Protocollo CVAY736F12301E1
Deliberazione - 359 - 03/07/2024
Deliberazione
N° 359
del 03/07/2024








